ClinicalTrials.gg
Enrolling by invitationNCT07399912ENHANCeUpdated Feb 10, 2026

Engaging Home-monitored Assessment to Navigate Clinical Decision-making

An interventional study of ENHANCe app and Teaching and training in Hypertension,Essential, sponsored by SingHealth Polyclinics. Enrolling by invitation at 1 site in Singapore. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by SingHealth Polyclinics · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This study is testing a new app called ENHANCe, which is designed to help family doctors manage patients with high blood pressure using readings taken at home.

Read the detailed description

The researchers want to find out if the app is easy to use in everyday clinic settings, whether doctors find it helpful and are willing to use it, and if it helps improve care. The study will involve 16 doctors and 100 patients with high blood pressure, split into two groups at two clinics. One group will use the ENHANCe app, which can read blood pressure data from different sources-including handwritten notes-and give doctors advice based on that information. The other group will receive regular care without the app. Over six months, researchers will collect feedback from doctors through surveys and group discussions at the end of the study. They'll also track how many people complete the study, how long clinic visits take, whether doctors follow the app's advice, and how well patients' blood pressure is controlled. The goal is to see if the app can help doctors make faster, better decisions and improve health outcomes for people managing their blood pressure at home.

02

Conditions studied

  • Hypertension,Essential

Keywords

  • Hypertension
  • Home blood pressure
  • Primary Care
  • Clinical decision support system
03

In context

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 75 are open to participants now.

This study's planned enrollment of 116 is below the median of 144 across 408 interventional studies indexed under Essential Hypertension.

Browse Essential Hypertension studies →

Lead sponsor

SingHealth Polyclinics is the lead sponsor of 23 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For primary care physicians:

  • PCPs aged 21 years and above.
  • Involved in the clinical management of patients with hypertension in the past six months.

For patients:

  • Patients aged 21 years and above
  • Documentation of hypertension diagnosis in EMR
  • Owns an HBP monitoring device

Exclusion criteria

Exclusion Criteria for patients:

  • Documentation of dementia diagnosis in EMR
  • Audio or visual impairments
  • Hypertensive urgency or emergency
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    Hypertension management using the Clinical Decision Support System

    All patients will have access to online educational resources throughout the study. After recruitment, they will receive a nurse-led education on HBP monitoring. The research team will train all primary care physicians (PCPs) on managing patients with hypertension using HBP records. The PCPs in the intervention group will be briefed on how the ENHANCe app works, and its recommendations. The ENHANCe app will be installed on designated mobile phones, and research staff will analyse HBP records during visits, documenting the output for PCPs to use. Based on the app's recommendations, patients will consult with intervention group PCPs 2-3 times throughout the study, with the last follow-up at 6 months. PCPs will complete a consult checklist after each visit. FGDs will be conducted with PCPs at the end of the study. The interviews will be recorded and transcribed for analysis.

    Device: ENHANCe app · Other: Teaching and training

  • Other
    Hypertension management as per usual care without a clinical decision support system

    All patients will have access to online educational resources throughout the study. After recruitment, they will receive a nurse-led education on HBP monitoring. The research team will train all primary care physicians (PCPs) on managing patients with hypertension using HBP records. Control group PCPs will manage patients using HBP records at their discretion, with a final follow-up scheduled at 6 months. PCPs will complete a consult checklist after each visit. Research staff will use the ENHANCe app to analyse BP diaries and document outcomes, but control group PCPs will not have access to the app or its results.

    Other: Teaching and training · Other: Usual care

Interventions

  • DeviceENHANCe app

    ENHANCe app is a prototype; it is a smartphone based clinical decision support (CDS) tool to manage patients with hypertension using their home blood pressure. The app will scan patients' home BP records from paper or mobile phone, and provide a recommendation to the doctor on how to manage their blood pressure. The patient will not need to use the device during the study period. However, the recommendation from the ENHANCe app will be available to the doctor to manage your blood pressure during the study period if the patient is in the intervention group.

  • OtherTeaching and training

    All patients will have access to online educational resources throughout the study. After recruitment, they will receive a nurse-led education on HBP monitoring. The research team will train all primary care physicians (PCPs) on managing patients with hypertension using HBP records.

  • OtherUsual care

    Physicians manage patients using HBP records at their discretion

06

What researchers measure

Primary outcomes

  1. Response rate of participants

    Participants agreeable to participate in the study

    Time frame: 6 months

  2. Agreement with the CDSS recommendation among PCPs

    Proportion of PCPs who agree with the CDSS recommendation in the two groups

    Time frame: 6 months

  3. Withdrawal rate

    Proportion of participants who withdrew

    Time frame: 6 months

  4. Study completion rate

    Proportion of participants who completed the intervention

    Time frame: 6 months

  5. Adverse event rates

    Proportion of adverse events reported in the two groups

    Time frame: 6 months

  6. Consult duration

    Consult time in the groups

    Time frame: 6 months

  7. Ease of home blood pressure record assessment among PCPS

    Ease of home blood pressure record assessment among PCPS in the two arms

    Time frame: 6 months

Secondary outcomes

  1. Proportion of CDSS recommendation followed by the PCPS

    Proportion of ENHANCe recommendations followed by the PCPs among the two groups

    Time frame: 6 months

  2. Blood pressure control status

    Blood pressure control status among patients in the two groups

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Oct 2026, 12 months after the start.

Of 70 non-industry interventional studies with no phase under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 47. This study's planned 12 months is below that.

Counting every sponsor, half of 80 studies reached it within 20 months; a quarter within 8 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2025
First posted
Feb 10, 2026
StartActual
Oct 1, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2026
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07399912
Lead sponsor
SingHealth Polyclinics
Collaborators
Nanyang Polytechnic
Responsible party
Sponsor
First posted
Feb 10, 2026
Start date
Oct 1, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Feb 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion